My Account | Shopping Cart | Contact
Oligonucleotides

Custom Synthesis
Diagnostic Services
Therapeutic Services
Randomers
OligoBuilder®
Request A Quote

  The Avecia-TriLink Alliance TriLink has teamed up with Avecia to enable you to easily transition from R&D and pre-clinical studies to clinical trials and commercial manufacture of therapeutic oligonucleotides. Working with this alliance minimizes your challenges and risks associated with transitioning from a research-grade vendor to an oligonucleotide development service and manufacturing company. We have harmonized our processes, so you can enjoy a smooth changeover when scaling up for clinical trials.
The common technology platform between TriLink and Avecia removes potential hurdles ensuring a worry-free transition from development through to the clinic.

Features Benefits
Common technology and analytical platforms Reduced risk of repeating pre-clinical investigations ahead of clinical trials
Common specifications Rapid pre-clinical to clinical transition
Close communication between customer and alliance
Reduced risk of missing key deadlines

Learn more about TriLink's Therapeutic Oligo Services
Read the press release about this program

Visit Avecia's website

Products | Ordering | Resources | About
© 2010 TriLink BioTechnologies, Inc. | All Rights Reserved